OEM News

Johnson & Johnson MedTech Launches Varipulse PFA in Asia-Pacific

It’s the first PFA technology to streamline ablation and mapping through a single, integrated workflow with the company’s Carto 3 system.

Author Image

By: Sam Brusco

Associate Editor

The Varipulse pulsed field ablation (PFA) platform. Photo: Johnson & Johnson MedTech.

Johnson & Johnson MedTech has launched its Varipulse pulsed field ablation (PFA) platform in the Asia-Pacific region.

The platform is used to perform catheter ablations for atrial fibrillation (AFib). It’s the first PFA technology to streamline ablation and mapping through a single, integrated workflow with the company’s Carto 3 system. The 3D electroanatomical cardiac mapping technology allows real-time visualization and supports precision, efficiency, reproducibility, and procedural accuracy.

It also, according to the company, enables safe and efficient therapy with minimal to no fluoroscopy exposure and is compatible with deep and/or conscious sedation. Varipulse received FDA approval in November 2024.

“The introduction of the VARIPULSE Platform in the Asia-Pacific region marks a significant advancement towards our goal of transforming atrial fibrillation care,” said Jing Li, Vice President, Electrophysiology & Neurovascular, Johnson & Johnson MedTech, Asia Pacific. “The adoption of the VARIPULSE Platform could demonstrate the unique value of integration with CARTO 3D to enhance efficiencies in the workflow of AFib treatment and improve patient outcomes.”

Unlike traditional ablation methods that use heat or cold, PFA uses short bursts of energy to affect heart tissue, potentially reducing the risk of damage to surrounding tissue such as the esophagus, pulmonary veins, and phrenic nerve.

“PFA, as a new type of energy, has the potential to further enhance the safety and efficacy of catheter ablation treatment, which is desirable for patients” said Dr. Yasuo Okumura, Professor and Department Head, Vice Hospital Director, Nihon University School of Medicine, Itabashi Hospital, Tokyo, Japan. “PFA is a relatively new medical technology, and therefore it is important to continue to assess its effectiveness and efficacy in Asia while ensuring proper use. But so far, we know that the integration of PFA technology with 3D mapping enables physicians to review their procedure in detail, and this contributes to quality of healthcare for patients.”

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters